Seres Therapeutics, Inc. (NASDAQ:MCRB) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Thank you for standing by. My name is Bella, and I will be your conference operator today. At this time, I would like to welcome everyone to the Q3 2024 Seres Therapeutics Earnings Conference Call.
Seres Therapeutics Q3 2024 Earnings Preview
Seres Therapeutics (NASDAQ:MCRB) is scheduled to announce Q3 earnings results on Wednesday, November 13th, before market open. The consensus EPS Estimate is -$0.00 and the consensus Revenue Estimate is $25.
Retractable Technologies: Q3 Earnings Snapshot
(RVP) on Thursday reported a loss of $1.9 million in its third quarter. On a per-share basis, the Little Elm, Texas-based company said it had a loss of 7 cents. The syringe and medical products maker posted revenue of $10.
PrimeEnergy: Q3 Earnings Snapshot
(PNRG) on Thursday reported earnings of $22.1 million in its third quarter. On a per-share basis, the Houston-based company said it had net income of $8.80. The investor in the oil and gas industry posted revenue of $69.
LG Display: Q3 Earnings Snapshot
On a per-share basis, the Seoul, Korea, Republic Of-based company said it had a loss of 26 cents. The maker of monitors and panels for TVs, phones and other products posted revenue of $5.03 billion in the period.
WidePoint: Q3 Earnings Snapshot
(WYY) on Wednesday reported
Abeona Therapeutics: Q3 Earnings Snapshot
Abeona Therapeutics shares have climbed 22% since the beginning of the year. The stock has risen 36% in the last 12 months. This story was generated by Automated Insights ( using data from Zacks Investment Research.
Dorel Industries: Q3 Earnings Snapshot
(DIIBF) on Thursday reported a loss of $21.9 million in its third quarter. On a per-share basis, the Westmount, Quebec-based company said it had a loss of 67 cents. Losses, adjusted for non-recurring costs,
Reeds: Q3 Earnings Snapshot
Reeds Inc. (REED) on Thursday reported
Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical ...
Seres Therapeutics Inc (MCRB) reports promising clinical results and strategic financial maneuvers, despite facing increased ...
Promising Developments and Financial Stability Drive Buy Rating for Seres Therapeutics
Analyst John Newman of Canaccord Genuity maintained a Buy rating on Seres Therapeutics (MCRB – Research Report), retaining the price ...
bovnews4h
Seres Therapeutics Inc (MCRB) Stock: Beyond the Surface of Its Performance?
On Wednesday, Seres Therapeutics Inc (MCRB) stock saw a decline, ending the day at $0.59 which represents a decrease of $-0.07 or -10.61% from the prior close of $0.66. The stock opened at $0.65 and ...
What's Next: Seres Therapeutics's Earnings Preview
Analysts are estimating that Seres Therapeutics will report an earnings per share (EPS) of $-0.24. Seres Therapeutics bulls ...
Seres Therapeutics Reports Q3 2024 Results and Strategic Progress
Seres Therapeutics Inc. ( (MCRB) ) has released its Q3 earnings. Here is a breakdown of the information Seres Therapeutics Inc. presented to ...
SFGate2d
Seres Therapeutics: Q3 Earnings Snapshot
CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Seres Therapeutics Inc. (MCRB) on Wednesday reported third-quarter earnings of $88.8 million. The Cambridge, Massachusetts-based company said it had ...
bovnews15d
Seres Therapeutics Inc (MCRB) Stock Surge: The Transparent Factors Exposed
On Tuesday, Seres Therapeutics Inc (MCRB) stock saw a modest uptick, ending the day at $0.77 which represents a slight increase of $0.07 or 10.00% from the prior close of $0.7. The stock opened at $0.
Seeking Alpha2d
MCRB Seres Therapeutics, Inc.
The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.
Benzinga.com1mon
Seres Therapeutics (NASDAQ:MCRB) Stock, Short Interest Report
Short interest in Seres Therapeutics Inc (NASDAQ:MCRB) increased during the last reporting period, rising from 15.94M to 17.22M. This put 15.76% of the company's publicly available shares short.
U.S. News & World Report29d
Seres Therapeutics Inc
Long-term investors should consider making these Fidelity mutual funds the core of their portfolio.